Edesa Biotech (NASDAQ:EDSA) Releases Quarterly Earnings Results

Posted by on May 14th, 2026

Edesa Biotech (NASDAQ:EDSA – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.25), FiscalAI reports.

Edesa Biotech Price Performance

NASDAQ EDSA traded down $0.63 on Thursday, hitting $14.61. 130,883 shares of the stock were exchanged, compared to its average volume of 1,085,382. Edesa Biotech has a 52-week low of $0.72 and a 52-week high of $20.32. The company has a market capitalization of $129.88 million, a price-to-earnings ratio of -12.70 and a beta of 1.26. The company’s 50-day moving average price is $8.35 and its two-hundred day moving average price is $3.95.

Insiders Place Their Bets

In other news, CEO Pardeep Nijhawan acquired 30,000 shares of the stock in a transaction on Friday, February 27th. The shares were purchased at an average cost of $2.22 per share, for a total transaction of $66,600.00. Following the transaction, the chief executive officer owned 371,702 shares in the company, valued at approximately $825,178.44. This trade represents a 8.78% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have purchased 73,571 shares of company stock worth $184,142. Insiders own 24.40% of the company’s stock.

Hedge Funds Weigh In On Edesa Biotech

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Diadema Partners LP purchased a new position in Edesa Biotech during the 4th quarter worth approximately $77,000. State Street Corp purchased a new position in Edesa Biotech during the 4th quarter worth approximately $27,000. DRW Securities LLC purchased a new position in shares of Edesa Biotech during the 4th quarter valued at $191,000. Finally, Susquehanna International Group LLP purchased a new position in shares of Edesa Biotech during the 3rd quarter valued at $36,000. 5.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Edesa Biotech in a report on Friday, March 27th. Wall Street Zen raised Edesa Biotech from a “sell” rating to a “hold” rating in a report on Sunday, April 5th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Edesa Biotech presently has an average rating of “Hold” and a consensus price target of $5.00.

Check Out Our Latest Report on Edesa Biotech

Edesa Biotech Company Profile

(Get Free Report)

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.

Featured Stories

Earnings History for Edesa Biotech (NASDAQ:EDSA)

Receive News & Ratings for Edesa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edesa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.